Xeris Biopharma (NASDAQ:XERS) Insider Steven Pieper Sells 5,000 Shares of Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Steven Pieper sold 5,000 shares of Xeris Biopharma stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $8.50, for a total value of $42,500.00. Following the transaction, the insider owned 1,361,053 shares in the company, valued at approximately $11,568,950.50. This represents a 0.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Steven Pieper also recently made the following trade(s):

• On Tuesday, July 7th, Steven Pieper sold 27,600 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.52, for a total value of $235,152.00.
• On Monday, July 6th, Steven Pieper sold 17,400 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.50, for a total value of $147,900.00.

Xeris Biopharma Trading Up 1.2%

NASDAQ XERS opened at $8.49 on Thursday. The firm has a market cap of $1.55 billion, a P/E ratio of -77.18 and a beta of 0.66. The company has a debt-to-equity ratio of 17.00, a current ratio of 2.12 and a quick ratio of 1.50. The stock’s 50-day moving average is $7.82 and its 200-day moving average is $6.81. Xeris Biopharma Holdings, Inc. has a one year low of $5.25 and a one year high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.19). Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 158.10%. The business had revenue of $92.10 million for the quarter, compared to the consensus estimate of $90.12 million. Sell-side analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Xeris Biopharma

Hedge funds and other institutional investors have recently bought and sold shares of the company. Royal Bank of Canada boosted its position in Xeris Biopharma by 1,411.2% during the 1st quarter. Royal Bank of Canada now owns 213,084 shares of the company’s stock worth $1,170,000 after acquiring an additional 198,984 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Xeris Biopharma by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock valued at $461,000 after purchasing an additional 3,594 shares during the last quarter. Millennium Management LLC lifted its position in shares of Xeris Biopharma by 19.0% in the first quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock worth $12,726,000 after purchasing an additional 369,420 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Xeris Biopharma by 75.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after purchasing an additional 1,199,435 shares in the last quarter. Finally, Caxton Associates LLP acquired a new position in Xeris Biopharma during the first quarter worth $170,000. Institutional investors and hedge funds own 42.75% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on XERS shares. Wall Street Zen downgraded shares of Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Weiss Ratings cut shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Tuesday. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $10.80.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.